CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
复制标题
DOI：
10.1080/14737159.2018.1427068
复制
发表时间：
2018-03
影响因子：
5.1
通讯作者：
Antonarakis ES
中科院分区：
文献类型：
--
作者：
Bastos DA;Antonarakis ES
前列腺癌是一种高度异质性的疾病，在所有阶段具有显著不同的预后。使用CellSearch测定的循环肿瘤细胞（CTC）计数增加（≥ 5）已被确定为可用于预测生存期的标志物之一，其附加值超出了目前可用的预后因素。最近，雄激素受体剪接变异体7（AR-V7）检测与接受新型雄激素受体信号传导（ARS）抑制剂（如阿比特龙和恩杂鲁胺，但不是紫杉烷化疗）治疗的去势抵抗性前列腺癌（CRPC）患者的结局较差相关。在本文中，作者回顾了CRPC中可用的生物标志物，并讨论了CTC衍生的AR-V7状态评估预后的价值及其指导晚期前列腺癌患者治疗选择的潜在作用的新数据。目前的证据支持AR-V7状态作为mCRPC患者的预后生物标志物和潜在预测生物标志物。作者预计，在晚期前列腺癌患者的序贯评估中纳入AR-V7状态和其他生物标志物（例如AR突变）将导致更合理地使用现有和未来的治疗方法，并显著改善患者的结局。
Prostate cancer is a highly heterogeneous disease, with remarkably different prognosis across all stages. Increased circulating tumor cell (CTC) count (≥ 5) using the CellSearch assay has been identified as one of the markers that can be used to predict surv<ival, with added value beyond currently available prognostic factors. Recently, androgen receptor splice variant 7 (AR-V7) detection has been associated with worse outcomes for patients with castration-resistant prostate cancer (CRPC) treated with novel androgen receptor-signaling (ARS) inhibitors such as abiraterone and enzalutamide but not taxane chemotherapies. In this manuscript, the authors review the available biomarkers in CRPC and discuss emerging data on the value of CTC-derived AR-V7 status to assess prognosis and its potential role to guide treatment selection for patients with advanced prostate cancer. Current evidence supports AR-V7 status as a prognostic biomarker and also as a potential predictive biomarker for patients with mCRPC. The authors expect that the incorporation of AR-V7 status and other biomarkers (e.g. AR mutations) in the sequential assessment of patients with advanced prostate cancer will lead to a more rational use of available and future therapies, with significant improvements in outcomes for our patients.
登录
查看更多内容
影响因子：
82.9
作者：
Beltran H;Prandi D;Mosquera JM;Benelli M;Puca L;Cyrta J;Marotz C;Giannopoulou E;Chakravarthi BV;Varambally S;Tomlins SA;Nanus DM;Tagawa ST;Van Allen EM;Elemento O;Sboner A;Garraway LA;Rubin MA;Demichelis F
通讯作者：
Demichelis F
DOI：
10.1158/1078-0432.ccr-15-0137
发表时间：
2016-03-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Beltran H;Jendrisak A;Landers M;Mosquera JM;Kossai M;Louw J;Krupa R;Graf RP;Schreiber NA;Nanus DM;Tagawa ST;Marrinucci D;Dittamore R;Scher HI
通讯作者：
Scher HI
影响因子：
11.5
作者：
Danila, Daniel C.;Heller, Glenn;Scher, Howard I.
通讯作者：
Scher, Howard I.
DOI：
10.1056/nejmoa1315815
发表时间：
2014-09-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Antonarakis ES;Lu C;Wang H;Luber B;Nakazawa M;Roeser JC;Chen Y;Mohammad TA;Chen Y;Fedor HL;Lotan TL;Zheng Q;De Marzo AM;Isaacs JT;Isaacs WB;Nadal R;Paller CJ;Denmeade SR;Carducci MA;Eisenberger MA;Luo J
通讯作者：
Luo J
影响因子：
23.4
作者：
Del Re, Marzia;Biasco, Elisa;Danesi, Romano
通讯作者：
Danesi, Romano